Levosimendan for the Treatment of Acute Heart Failure Syndromes: Time to Identify Subpopulations of Responding Patients

American Journal of Cardiology

Volumn 99, Issue 1, 2007, Pages 146-147

  Parissis, John T ^a   Farmakis, Dimitrios ^a   Bistola, Vassiliki ^a   Adamopoulos, Stamatios ^a   Kremastinos, Dimitrios Th ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; LEVOSIMENDAN;

ACUTE HEART FAILURE; CLINICAL PRACTICE; HUMAN; LETTER; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; PATIENT SELECTION; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS;

EID: 33845715098     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.10.007     Document Type: Letter

References (9)

1. Follath F., Cleland J.G.F., Just H., Papp J.G.Y., Scholz H., Peuhkurinen K., Harjola V.P., Mitrovic V., Abdalla M., Sandell E.-P., and Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360 (2002) 196-202
2. Moiseyev V.S., Poder P., Andrejevs N., Ruda M.Y., Golikov A.P., Lazebnik L.B., Kobalava Z.D., Lehtonen L.A., Laine T., Nieminen M.S., and Lie K.I. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study. (RUSSLAN). Eur Heart J 23 (2002) 1422-1432
3. De Luca L., Colucci W.S., Nieminen M.S., Massie B.M., and Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 27 (2006) 1908-1920
4. Adamopoulos S., Parissis J.T., Iliodromitis E.K., Paraskevaidis I., Tsiapras D., Farmakis D., Karatzas D., Gheorghiade M., Filippatos G.S., and Kremastinos D.T. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 98 (2006) 102-106
5. Parissis J.T., Panou F., Farmakis D., Adamopoulos S., Filippatos G., Paraskevaidis I., Venetsanou K., Lekakis J., and Kremastinos D.T. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 96 (2005) 423-426
6. Parissis J.T., Adamopoulos S., Antoniades C., Kostakis G., Rigas A., Kyrzopoulos S., Iliodromitis E., and Kremastinos D. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93 (2004) 1309-1312
7. Parissis J.T., Filippatos G., Farmakis D., Adamopoulos S., Paraskevaidis I., and Kremastinos D. Levosimendan for the treatment of acute heart failure syndromes. Expert Opin Pharmacother 6 (2005) 2741-2751
8. Parissis J.T., Adamopoulos S., Farmakis D., Filippatos G., Paraskevaidis I., Panou F., Iliodromitis E., and Kremastinos D.T. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 92 (2006) 1768-1772
9. Giannakoulas G., Giannoglou G., Vassilikos V., Martiadou K., Kalpidis P., Parharidis G., and Louridas G. Clinical significance of acute neurohormonal response after levosimendan Streatment. Am J Cardiol 98 (2006) 1123-1124